<?xml version="1.0" encoding="iso-8859-1" standalone="no" ?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>PRO000000000000509995</messagenumb>
    <messagesenderidentifier>EMDSERONO</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125161537</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">CA-US-EMD Serono, Inc.-7188370</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20130125</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>1</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20130116</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20130116</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">CA-Merck KGaA-7188370</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <linkedreport>
      <linkreportnumb>CA-DE-Merck KGaA-7188355</linkreportnumb>
    </linkedreport>
    <primarysource>
      <reporterfamilyname>Unknown</reporterfamilyname>
      <reportercountry>CA</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <senderorganization>US-EMD Serono, Inc.</senderorganization>
      <senderdepartment>US Product Surveillance and Quality Assurance</senderdepartment>
      <sendertitle>Dr</sendertitle>
      <sendergivename>Daryl</sendergivename>
      <senderfamilyname>Dawson</senderfamilyname>
      <senderstreetaddress>One Technology Place</senderstreetaddress>
      <sendercity>Rockland</sendercity>
      <senderstate>MA</senderstate>
      <senderpostcode>02370</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>781-681</sendertel>
      <sendertelextension>2564</sendertelextension>
      <sendertelcountrycode>+1</sendertelcountrycode>
      <senderfax>781-681</senderfax>
      <senderfaxextension>2961</senderfaxextension>
      <senderfaxcountrycode>+1</senderfaxcountrycode>
      <senderemailaddress>usps@emdserono.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>US-A-Food and Drug Administration</receiverorganization>
      <receiverdepartment>AERS</receiverdepartment>
      <receivertitle>Mr</receivertitle>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>CDER</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
      <receivercity>Rockville</receivercity>
      <receiverstate>MD</receiverstate>
      <receiverpostcode>20851</receiverpostcode>
      <receivercountrycode>US</receivercountrycode>
      <receivertel>3017709299</receivertel>
      <receivertelcountrycode>001</receivertelcountrycode>
      <receiverfax>3017706614</receiverfax>
      <receiverfaxcountrycode>001</receiverfaxcountrycode>
      <receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
    </receiver>
    <patient lang="en">
      <patientonsetage>56</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>70</patientweight>
      <patientheight>157</patientheight>
      <patientsex>2</patientsex>
      <reaction>
        <primarysourcereaction lang="en">BACTERIAL INFECTION</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10060945</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10060945</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">DYSPHAGIA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10013950</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10013950</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">GAIT DISTURBANCE</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10017577</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10017577</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">HYPERAESTHESIA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10020568</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10020568</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">HYPOAESTHESIA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10020937</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10020937</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">LYMPHADENOPATHY</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10025197</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10025197</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">MULTIPLE SCLEROSIS</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10028245</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10028245</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">NAUSEA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10028813</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10028813</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">OROPHARYNGEAL PAIN</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10068319</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10068319</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">TACHYCARDIA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10043071</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10043071</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">PARAESTHESIA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10033775</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10033775</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">BODY TEMPERATURE INCREASED</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10005911</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10005911</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">HEADACHE</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10019211</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10019211</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">INJECTION SITE SWELLING</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10053425</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10053425</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">INJECTION SITE INFLAMMATION</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10022078</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10022078</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">INJECTION SITE ERYTHEMA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10022061</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10022061</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>1</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REBIF</medicinalproduct>
        <drugauthorizationnumb>103780</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugstructuredosagenumb>22</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosageform lang="en">Injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
        <actiondrug>5</actiondrug>
        <activesubstance>
          <activesubstancename>INTERFERON BETA-1A</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10060945</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10060945</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10013950</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10013950</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10017577</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10017577</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10020568</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10020568</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10020937</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10020937</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10025197</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10025197</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10028245</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10028245</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10028813</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10028813</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10068319</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10068319</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10043071</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10043071</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10033775</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10033775</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10005911</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10005911</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10019211</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10019211</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10053425</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10053425</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022078</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022078</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022061</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022061</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Bentylol</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Diovan</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Folic acid</medicinalproduct>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Lipitor</medicinalproduct>
        <drugdosageform lang="en">Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Nu Diclo SR SRT (diclofenac)</medicinalproduct>
        <drugdosageform lang="en">Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Pariet</medicinalproduct>
        <drugdosageform lang="en">Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Tiazac XC</medicinalproduct>
        <drugdosageform lang="en">Tablet</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical lang="en">This spontaneous case report from an other health professional in Canada was received via the Canadian Health Authority (000304533) at Merck Serono on 16 Jan 2013.
A 56-year-old female patient experienced bacterial infection, dysphagia, gait disturbance, hyperaesthesia, hypoaesthesia, lymphadenopathy, multiple sclerosis, nausea, oropharyngeal pain, tachycardia, paraesthesia, body temperature increased, headache, injection site swelling, injection site inflammation and injection site erythema while being treated with Rebif.
All the events led to patient's hospitalization.
No relevant medical history was reported.
The patient's concomitant medications included Bentylol (dicyclomine), Diovan (valsartan), folic acid, Lipitor (atorvastatin calcium) tablet, Nu Diclo SR SRT (diclofenac) tablet (extended release), Pariet (rabeprazole) tablet (enteric coated) and Tiazac XC (diltiazem) tablet (extended release). No further information was provided.
The patient received Rebif liquid (interferon beta 1a) at a dose of 22 mcg three times a week subcutaneously from an unknown date for an unknown indication.
On an unknown date, the patient experienced bacterial infection, dysphagia, gait disturbance, hyperaesthesia, hypoaesthesia, lymphadenopathy, multiple sclerosis, nausea, oropharyngeal pain, tachycardia, body temperature increased, paraesthesia, headache, injection site swelling, injection site inflammation and injection site erythema.
At the time of reporting, action taken with Rebif therapy was not reported.
At the time of reporting, all the events had resolved.
The reporter did not provide any causality assessment.

This case is linked to 7188355.</narrativeincludeclinical>
        <sendercomment lang="en">Bacterial infection [Bacterial infection], dysphagia [Dysphagia], gait disturbance [Gait disturbance], hyperaesthesia [Hyperaesthesia], hypoaesthesia [Hypoaesthesia], lymphadenopathy [Lymphadenopathy], multiple sclerosis [Multiple sclerosis], nausea [Nausea], oropharyngeal pain [Oropharyngeal pain], tachycardia [Tachycardia], paraesthesia [Paraesthesia], body temperature increased [Body temperature increased], headache [Headache], injection site swelling [injection site swelling], injection site inflammation [Injection site inflammation], injection site erythema [Injection site erythema] in a 56-year-old female patient, an unspecified period of time after the first administration of Rebif for unknown indication.
Temporal relationship: compatible. Dechallenge: not applicable (action taken with Rebif not reported).
Alternative explanations: Gait disturbance, dysphagia, hyperaesthesia and hypoaesthesia could be explained by the concurrent multiple sclerosis (possible Rebif indication). The concomitant medications may have contributed to the occurrence of headache, paraesthesia, hypoaesthesia body temperature increased and nausea.
Causality by reporter (other health professional): not provided.
Causality by company: In absence of sufficient information to fully assess the case, all unlisted events have been assessed as causally related to Rebif. All listed events are assessed as related to Rebif.
Bacterial infection, Dysphagia, Gait disturbance, Hyperaesthesia, Hypoaesthesia, Lymphadenopathy, Multiple sclerosis, Nausea, Oropharyngeal pain, Tachycardia, Paraesthesia are unlisted and the other events are listed for Rebif as per reference safety information.
Infections and infestations (including bacterial infection) are closely monitored in patients treated with Rebif.

Follow-up information requested (Rebif therapy details, medical history, AEs onset dates, action taken and reporter's assessment).</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr>
